Tenaya Therapeutics Inc.

TNYA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.67

-$0.01 (-1.37%)

At close: Sep 21, 2026, 4:00 PM ET

$0.68

+$0.01 (+1.64%)

Pre-market: Sep 22, 2026, 9:21 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.37%

(1D)

Rating

Updated: Aug 18, 2026

28.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $146.21M

1D Range

0.67 0.71

52W Range

0.53 2.35

Valuation (TTM)

PE -1.26

PB 2.11

EV/EBITDA -0.75

Valuation (NTM)

Forward PE 10.73

Forward PEG 0.05

Price Target $2.33

Cash Flow

FCF Yield -49.1%

SBC Adj. FCF Yield -57.2%

SBC Impact -16.4%

Margins

Gross Margin 263.7%

Operating Margin -7929.9%

FCF Margin -5380.8%

Growth (CAGR)

Revenue 3Y | 5Y 150.0% | 100.0%

Dil EPS 3Y | 5Y 51.0% | 35.4%

FCF 3Y | 5Y 16.3% | 13.7%

Returns

ROA -110.2%

ROE -108.0%

ROIC -136.8%

Financial Health

Net Cash

$78.09M

Current Ratio 4.52

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gen...

Sector Healthcare

Industry Biotechnology

Employees 70

IPO Date Jul 29, 2021

Website www.tenayatherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+198.51%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞